Novozymes A/S (0Q4U) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Novozymes A/S DKK 214, price DKK 418, upside -48.7%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range kr 264.63 – kr 498.43 · fair‑value band kr 152.32 – kr 277.70 · the kr 417.70 price screens above the kr 214.46 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America.
Show more
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel. In addition, it provides dishwashing, home cleaning, laundry, medical, and industrial and institutional cleaning services; gastrointestinal, immune, mental, women's, children's cardiometabolic, and oral human health solutions. Further, the company offers corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; silage, diary and beef cattle, poultry, swine, aquaculture solutions; pet care solutions; leather and textiles solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions; and distilling, oils and fats, sustainable plastic solutions. Additionally, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S is headquartered in Lyngby, Denmark.
Stock analysis
Novozymes A/S (0Q4U) currently trades at kr 417.70, while our model-based Fair Value estimate is kr 214.46, 48.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 213.11 per share, and 0 of the 23 models we run sit above the kr 417.70 price.
Bear case: the Asset-Based group reads lowest at kr 35.47, and 23 of the 23 models stay below the price. Evidence for this calculation is high.
Scenario range: kr 152.32 (bear) to kr 277.70 (bull), the price of kr 417.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Novozymes A/S reported revenue of 15.0B DKK in FY2021 versus 14.5B DKK in FY2017, a compound +0.7%/yr. Reported net income was 3.1B DKK in FY2021, compounding +0.2%/yr from FY2017.
Key figures
Market cap 93.3B DKK (≈ $14.0B) · P/S ratio 22.2 · Dividend yield 0.2% · Net margin 21.0% · Return on equity 5.4% · Return on assets (EBIT) 19.1% · Operating margin 24.4% · Revenue growth (YoY) +3.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 24% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −39% fair-value upside, at −49%, 0Q4U screens richer than that median.
Fair Value models
Bear kr 152.32Fair Value kr 214.46Bull kr 277.70
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+6.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.3%
’17
’18
’19
’20
’21
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
27.0% (2017) → 26.8% (2021)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Novozymes A/S Fair Value". https://www.fairvalue-calculator.com/stock/0Q4U
Frequently asked questions
Is Novozymes A/S (0Q4U) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of kr 214.46 versus a price of kr 417.70, about −49% upside (overvalued).
What is the fair value of 0Q4U?
Our model-based fair value for Novozymes A/S is kr 214.46 (as of Oct 3, 2026), built from audited fundamentals. The current price: kr 417.70.
What is the quality score of 0Q4U?
Novozymes A/S has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Novozymes A/S (0Q4U)?
Our model-based price target is the fair value of kr 214.46 (as of Oct 3, 2026) from 23 valuation models. Cautious scenario kr 152.32, optimistic scenario kr 277.70. It is a calculation from audited fundamentals, not an analyst target.
What is the Novozymes A/S stock forecast for 2026?
Our models put fair value at kr 214.46, about −49% upside versus a price of kr 417.70 (overvalued). Cautious scenario kr 152.32, optimistic scenario kr 277.70. The calculation is refreshed regularly with new filings.
Does Novozymes A/S pay a dividend?
Novozymes A/S currently shows a dividend yield of about 0.21% relative to its recent price (as of Oct 3, 2026).
What is the intrinsic value of Novozymes A/S (0Q4U)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Novozymes A/S it is kr 214.46 per share (as of Oct 3, 2026), against a price of kr 417.70. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Novozymes A/S stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 0Q4U trades above its calculated fair value: price kr 417.70, fair value kr 214.46, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0Q4U?
No. The price is what the market pays today (kr 417.70); the fair value is what the company's own numbers justify (kr 214.46). For Novozymes A/S the two are kr 203.24 per share apart. That gap is exactly why we show both numbers side by side.
How much is Novozymes A/S worth?
The market values Novozymes A/S at about 93.3B DKK (market capitalisation, as of Oct 3, 2026). Per share that is kr 417.70; our models calculate a fair value of kr 214.46 per share.
What do the bullish and bearish scenarios say about 0Q4U?
Our models span a range for Novozymes A/S: cautious scenario kr 152.32, base kr 214.46, optimistic kr 277.70 per share (as of Oct 3, 2026, price kr 417.70). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0Q4U from its 52-week high?
Novozymes A/S trades at kr 417.70, about 9% below its 52-week high of kr 459.35 and 24% above the low of kr 336.59 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 214.46 is for.
Which stocks are comparable to Novozymes A/S?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Novozymes A/S stock attractive at the current price?
The data as of Oct 3, 2026: price kr 417.70, calculated fair value kr 214.46 (−49%), Quality Score 67/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0Q4U calculated?
We run Novozymes A/S through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 214.46, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Novozymes A/S itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Novozymes A/S (0Q4U)?
The closing price on Oct 2, 2026 was kr 417.70. Our model-based fair value is kr 214.46, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Novozymes A/S right now?
The price sits above even our optimistic bull case (kr 277.70). The favourable scenario is already priced in. Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 152.32 to kr 277.70) leaves room in how you read the outcome.
Key figures of Novozymes A/S
How large is the market capitalisation of Novozymes A/S (0Q4U)?
The market capitalisation of Novozymes A/S is 93.3B DKK (≈ $14.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Novozymes A/S (0Q4U)?
The price-to-sales ratio of Novozymes A/S is 22.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Novozymes A/S (0Q4U)?
The dividend yield of Novozymes A/S is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Novozymes A/S (0Q4U)?
The net margin of Novozymes A/S is 21.0% (fiscal year 2021). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Novozymes A/S (0Q4U)?
The return on equity (ROE) of Novozymes A/S is 5.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Novozymes A/S (0Q4U)?
On an EBIT basis the return on assets of Novozymes A/S is 19.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Novozymes A/S (0Q4U)?
The operating margin of Novozymes A/S is 24.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Novozymes A/S (0Q4U)?
Revenue at Novozymes A/S is growing +3.9% versus a year earlier (3y avg +1.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Novozymes A/S (0Q4U)?
Earnings per share at Novozymes A/S are growing +7.5% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
